Compare ADMA Biologics Inc (ADMA) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Harmony Gold Mining Co. — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Harmony Gold Mining Co. trades at $19.79 (market cap $12.24B). The key difference: Harmony Gold Mining Co. is far larger — about 5.5× ADMA Biologics Inc's market cap, and Harmony Gold Mining Co. pays a 2.09% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HMY | |
|---|---|---|
Market Cap | $2.22B | $12.24B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $26.04 |
52-Week Low | $7.60 | $12.61 |
Enterprise Value | $2.29B | $12.58B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
Harmony Gold (HMY) trades at $19.89, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported robust 2024 results with $61.38B revenue and $8.59B net income, supported by a strategic pivot toward gold-copper production. Recent earnings have been mixed, with a Q4 2025 miss but prior beats.
The outlook is cautiously optimistic due to diversification benefits and solid cash flow, but risks include Fed rate sensitivity and execution challenges. Analyst sentiment is mixed with a majority Hold rating, reflecting balanced near-term prospects amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
